Vaxxas is commercializing a novel vaccination technology that dramatically enhances the performance of existing and next-generation vaccines. Vaxxas' HD-MAP technology uses a patch with thousands of vaccine-coated microprojections that is applied to the skin for a few seconds to efficiently deliver vaccine to the abundant immune cells immediately below the skin surface.